Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 55 results.

Thumbnail for Blastic Crisis of CML in a Patient With Underlying CLL.

CML - 713

Blastic Crisis of CML in a Patient With Underlying CLL.

Ricardo Romano

Poster Presenter: Ricardo Romano

Thumbnail for Efficacy of Olverembatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) With Prior Resistance to Ponatinib or Asciminib and ASXL1 Mutations

CML - 731

Efficacy of Olverembatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) With Prior Resistance to Ponatinib or Asciminib and ASXL1 Mutations

Elias Jabbour

Poster Presenter: Elias Jabbour

Thumbnail for Comparison of the Incidence of Cardiovascular Adverse Events in Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors With Representatives of the General Population

CML - 797

Comparison of the Incidence of Cardiovascular Adverse Events in Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors With Representatives of the General Population

Nadezhda Shnalieva

Poster Presenter: Nadezhda Shnalieva

Thumbnail for Mutation analysis of ABL kinase domain in Tunisian CML patients treated with tyrosine kinase inhibitors

CML - 899

Mutation analysis of ABL kinase domain in Tunisian CML patients treated with tyrosine kinase inhibitors

Rim Frikha

Poster Presenter: Rim Frikha

Thumbnail for Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

CML - 913

Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

Ali Turunc

Poster Presenter: Ali Turunc

Thumbnail for Asciminib (ASC) in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Analysis (IA) Efficacy and Safety Results of the Phase 2 ASC2ESCALATE Trial in the Cohort of Newly Diagnosed Patients

CML - 918

Asciminib (ASC) in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Analysis (IA) Efficacy and Safety Results of the Phase 2 ASC2ESCALATE Trial in the Cohort of Newly Diagnosed Patients

Moshe Levy

Poster Presenter: Moshe Levy

Thumbnail for Comparable Survival, Divergent Mortality: Five-Year Outcomes of Chronic Myeloid Leukemia in a Peruvian Public Hospital

CML - 926

Comparable Survival, Divergent Mortality: Five-Year Outcomes of Chronic Myeloid Leukemia in a Peruvian Public Hospital

Cesar Copaja-Corzo

Poster Presenter: Cesar Copaja-Corzo

Thumbnail for Validation of a Prognostic Score in Blast Phase CML: A Cure CML Consortium Analysis

CML - 929

Validation of a Prognostic Score in Blast Phase CML: A Cure CML Consortium Analysis

Akriti G Jain

Poster Presenter: Akriti G Jain

Thumbnail for Treatment Response of Dasatanib in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients

CML - 969

Treatment Response of Dasatanib in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients

Baalamurugan K T

Poster Presenter: Baalamurugan K T

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.